



IMPLICATIONS OF ANTIBIOTIC RESISTANCES PRODUCED BY PHENOTHIAZINES IN *Mycobacterium tuberculosis*

Sanchayita Debnath¹, Debalina Sinha Roy², Bidisha Ghosh³, Shauroseni Palchoudhuri², Sukhen Das³, Sujata G. Dastidar^{2*}

Address(es):

¹Department of Botany, Sri Chaitanya College, Habra, North 24-Parganas, West Bengal, India.

²Department of Microbiology, Herbicare Healthcare Bio-Herbal Research Foundation, Boral, Kolkata 700154, India.

³Department of Physics, Jadavpur University, Kolkata 700032, India.

*Corresponding author: jumicrobiol@yahoo.co.in

doi: 10.15414/jmbfs.2016.6.2.781-785

ARTICLE INFO

Received 30. 10. 2015
Revised 10. 2. 2016
Accepted 21. 3. 2016
Published 3. 10. 2016

Regular article



ABSTRACT

Several chemotherapeutic agents applied to human beings for past few decades for different ailments, have been found to possess potent antitubercular activity. Two such agents, methdilazine (Md) and promethazine (Pz) were used to select mycobacterial mutants resistant to themselves at different levels and tested to determine if such mutants simultaneously developed cross-resistance to known antitubercular drugs. Mutants were produced by application of a heavy inoculum on Lowenstein-Jensen medium containing Md (or Pz) at concentrations higher than their respective minimum inhibitory concentrations (MICs). These were then tested to find out if such mutants have changed their resistogramme pattern with respect to the test antitubercular agents. Certain first-step Md-mutants became simultaneously resistant to ethambutol and pyrazinamide; while the step-2 Md-mutants revealed further increase in resistance to these agents along with resistance to isoniazid, rifampicin and streptomycin as well. In the study with Pz it was noted that many mutants showed distinctly higher levels of resistance to all the test drugs, particularly to isoniazid, pyrazinamide and streptomycin. The levels of MIC were distinctly high in many mutants. These observations on cross-resistances seem to be best explained on the basis of a reduction in cell-membrane permeability acting in a non-specific manner. The role of such a cross-resistance may possibly be accounting for an overall increase in the MICs of many drugs against several groups of microorganisms including *Mycobacterium tuberculosis* and other species of *Mycobacterium* during the last five decades.

Keywords: Cross-resistance; *Mycobacterium tuberculosis*; phenothiazines; mutants; antitubercular agents

INTRODUCTION

Tuberculosis is a remarkably high risk communicable disease of human beings. The causative organism *Mycobacterium tuberculosis* is airborne and is often transmitted among people of lower income group suffering from malnutrition and immunological deficiencies. The World Health Organization (WHO, 2013) reported a total of 8.6 million new cases of tuberculosis and 1.3 million deaths due to this infection in 2012. In the treatment regime referred as Directly Observed Treatment Schedule (DOTS) isoniazid, rifampicin, ethambutol and pyrazinamide are administered for two months after presumptive diagnosis. Subsequently isoniazid and rifampicin are continued in the same patients for 4 to 7 months depending on the severity of infection. However, now there are more virulent forms designated as multi-drug resistant strains that are resistant to isoniazid and rifampicin. Apart from this many strains are found to be resistant to isoniazid, rifampicin, streptomycin, any fluoroquinilone plus any of the antitubercular injectables like amikacin/ kanamycin/ capreomycin. Such strains have evolved due to misuse or overuse of the scheduled drugs or failure in continuation of the correct therapy. These strains may also arise if the treatment schedule is allowed to continue for more than 12 months. Simultaneous application of so many drugs creates sufficient pressure for the causative organism to select multi-drug resistant mutants. Such a situation could not have occurred by a simple mode of action since different drugs have different sites of action. The modes of action of anti-tubercular drugs are very varied, although structurally similar drugs usually have the same mutated target. The occurrence and prevalence of tuberculosis by drug resistant organisms initiated systematic search for antimycobacterial agents from various existing pharmacological agents by several groups of researchers in different parts of the world. Such studies revealed that antipsychotic and antihistaminic phenothiazines possess powerful antitubercular action. Most potent among these were thioridazine, methdilazine, trifluoperazine, chlorpromazine and promethazine (Molnar et al., 1977; Kristiansen and Vergemann, 1986; Ratnakar and Murthy, 1993; Chakrabarty et al., 1993; Dutta et al., 2009; Crowle et al., 1992; Amaral et al., 1996; van Ingen et al., 2009; Advani et al., 2012;

Kristiansen et al., 2015). These were reported to be simultaneously active against a large number of Gram positive and Gram negative bacteria as well (Kristiansen, 1979; Radhakrishnan et al., 1999; Mazumdar et al., 2001; Dastidar et al., 1995; Dastidar et al., 2004; Dastidar et al., 2013).

Occurrence of cross-resistances among aminoglycosides in *Mycobacterium tuberculosis* was reported as far back as 1959 by several workers (Torii et al., 1959; Tsukamura, 1959). Koseki & Okamoto (1963) presented evidences for a significant change in resistance to viomycin caused by development of resistance to capreomycin in *Mycobacterium tuberculosis*. Tsukamura (1969) while trying to produce drug resistant mutants in the laboratory found that highly kanamycin resistant *M.tuberculosis* strains were resistant to capreomycin and strains moderately resistant to kanamycin were susceptible to capreomycin. He further observed that experimentally produced capreomycin resistant strains failed to develop resistance to kanamycin. Such a one way cross-resistance relationship was observed among many other aminoglycosides (Tsukamura, 1974). Tsukamura and Mizuno (1975) while trying to determine cross-resistance relationships among aminoglycosides in *M.tuberculosis* reported that resistances to several antibiotics could be produced by a single mutation to any one of the agents. In 2005 Maus et al attempted to analyze cross-resistance to capreomycin, kanamycin, amikacin and viomycin in *M.tuberculosis* at molecular level. According to these authors mutation of the *thyA* gene confer capreomycin and viomycin resistance in *M.tuberculosis*. It is known that in mutations in the 16S rRNA gene (*rrs*) have been associated with resistance to all these four drugs (Suzuki et al., 1998). Maus et al (2005) reported three *rrs* mutations in their *M.tuberculosis* test strains each of which was associated with a particular cross-resistance pattern. They opined that when *M.tuberculosis* strains are exposed to one or two drugs phenotypic and genotypic differences can be seen in the development of antibiotic cross-resistance.

In the present study we have tried to determine the ability of antitubercular phenothiazine compounds methdilazine and promethazine to produce mutants resistant to themselves and also to detect if such mutants develop cross-resistances to known antitubercular agents.

MATERIAL AND METHODS

Strains

M. smegmatis 789, *M. phlei* L1, *M. avium* 724, *M. flavescens* 1541, *M. gordonae* 1324, *M. intracellulare* 1406, *M. tuberculosis* H₃₇Rv 102 and *M. tuberculosis* H₃₇Ra 16 were obtained from Dr V.M. Katoch, the then Director of National JALMA Institute for Leprosy and other Mycobacterial Diseases, Agra, India. Remaining three strains *M. tuberculosis* Bajaj 1, J15, and N23 were obtained from Dr A.N. Chakrabarty, Department of Medical Microbiology & Parasitology, Calcutta University College of Medicine, Kolkata, India. All the organisms were received as live culture slants in Lowenstein-Jensen Medium (LJM) from both the institutions and maintained in the same medium throughout the study.

Media

All the biological components were obtained from Oxoid (UK). Kirchner's Liquid Medium (KLM) and LJM were prepared as per established protocol (Barrow and Feltham, 2003). The growth was confirmed for *Mycobacterium* spp. after performing Z-N staining and different biochemical tests, like niacin test, nitrate reduction test and catalase test (Kamerbeek et al., 1997).

Overlay medium

This was prepared with 7H10 agar base, distilled water and glycerol, distributed in 2mL amounts and sterilized by autoclaving.

Inoculation

The known standard strains *M. tuberculosis* H₃₇Rv 102 and H₃₇Ra 16 along with all the other mycobacteria were grown in KLM, vortexed, diluted and standardized. Mcfarland standard 0.5 (in turbidity standard; the turbidity standard was prepared by adding 0.5 ml of a barium chloride solution to 99.5 ml of 1% H₂SO₄) was routinely taken for inoculation of all the strains and their mutants.

Media containing antitubercular drugs and other selecting agents

The agents were obtained in pure dry powder form from their manufacturers in India and stored at 4°C. To 2ml of overlay medium was added, any of the following agents: isoniazid acid hydrazide (INH), rifampicin (Rf), ethambutol (Eb), pyrazinamide (Pz), streptomycin (Sm), methdilazine (Md) and

promethazine (Pz). The final concentration (µg/ml) of each of the agents were: 1,2,5,10,25,50,100, 200,400, 800, 1000 and 2000; these were added to the overlay medium before being allowed to flow over the freshly prepared LJM slants. All such bottles were inoculated for appearance of growth.

Determination of Minimum Inhibitory Concentration (MIC)

The MIC of the agents for different strains of *Mycobacterium* and their mutants were determined by inoculating the media as described above and incubating at 37°C. Appearance of growth was checked every day up to 3 weeks. Adequate strain and media controls were run throughout the tests.

Production and isolation of Md and Pz mutants

This was done by application of a heavy inoculum on LJM containing Md, the amount being higher than the MIC of the organism with respect to the agent. As the mutants developed they were designated as Step 1 mutants and were inoculated on LJM containing still higher amount of Md. The colonies developing on such a medium were designated as Step 2 mutant. In this way higher steps of mutants were selected with both Md and Pz. The relationship of the mutants with respect to the original wild types was determined with the help of various known and standardized morphological and biochemical parameters as described earlier.

RESULTS AND DISCUSSION

Sensitivity of bacteria

The minimum inhibitory concentration (MIC) of INH, Rf, Eb, Py, Sm, Md and Pz with respect to 20 strains of *Mycobacterium* is presented on Table 1. These strains were selected on the basis of previous studies that had revealed that most of these were sensitive to the test drugs including the phenothiazines at low concentrations. The MIC of INH, Py and Sm in the recent clinical isolates *M. tuberculosis* Bajaj 1, J15 and N23 was rather high. In *M. tuberculosis* Bajaj 1, the MIC of INH and Sm was 25µg/ml. The strain N23 was even more resistant, the MIC of Py and Sm was as high as 50µg/ml. With respect to the phenothiazines, the MIC values ranged between 10 and 25µg/ml in most of the test strains; however, in case of Bajaj 1, J15 and N23 the MIC of Md and Pz was 50µg/ml.

Table 1 Minimum inhibitory concentration (MIC) of anti-tubercular drugs, methdilazine and promethazine against various strains of *Mycobacterium*

Mycobacterium	MIC (µg/ml)						
	INH	Rf	Eb	Py	Sm	Md	Pz
<i>M. smegmatis</i> 789	2	2	2	5	2	25	10
<i>M. smegmatis</i> 1546	2	2	2	5	2	10	25
<i>M. fortuitum</i> 1529	2	2	2	2	5	10	25
<i>M. scrofulaceum</i> 1323	2	1	2	2	2	10	10
<i>M. avium</i> 724	5	5	10	2	10	25	25
<i>M. gordonae</i> 1324	2	2	2	5	2	10	10
<i>M. phlei</i> L1	5	2	2	10	2	25	25
<i>M. marinum</i> 50	2	2	5	5	2	25	25
<i>M. intracellulare</i> 1406	5	5	5	5	2	10	25
<i>M. flavescens</i> 1541	2	2	5	5	2	10	10
<i>M. terrae</i> 1450	5	2	2	5	2	10	10
<i>M. tuberculosis</i> H ₃₇ Ra16	2	2	2	5	2	5	25
<i>M. tuberculosis</i> H ₃₇ Rv102	2	2	5	5	2	10	25
<i>M. tuberculosis</i> Bajaj1	25	5	5	5	25	50	50
<i>M. tuberculosis</i> J15	25	5	10	25	25	50	50
<i>M. tuberculosis</i> N23	25	5	5	50	50	50	50
<i>M. tuberculosis</i> K1	2	1	2	5	2	10	25
<i>M. tuberculosis</i> 2	2	1	5	2	2	10	25
ICRC bacillus	2	2	2	5	2	10	10
"Skinsness" bacillus	2	2	5	5	2	10	25

INH, isoniazid acid hydrazide; Rf, rifampicin; Eb, ethambutol; Py, pyrazinamide; Sm, streptomycin; Md, methdilazine; Pz, promethazine

Selection of mutants

All the 20 strains of *Mycobacterium* spp. were investigated for production of highly resistant Md mutants; of these 11 failed to produce mutants even after repeated tests. Nine strains of mycobacteria passaged on low but step-wise gradually rising concentrations of Md finally produced mutants of high resistance. The mutants were accepted only when the identification tests particularly with respect to cultural morphology in LJM coupled with acid fastness, established that they belonged to the respective wild-types. Following

the same principle Pz mutants were selected. It may be pointed out here that *M. tuberculosis* Bajaj 1, J15, N23, H₃₇Rv102 and H₃₇Ra16 were able to develop fairly resistant mutants with respect to both Md and Pz. Among the others *M. phlei* L1, *M. flavescens* 1541, *M. avium* 724 and *M. gordonae* 1324 were able to produce Md-resistant mutants while 4 other strains of *Mycobacterium* could successfully develop Pz resistant mutants. The remaining 7 strains were unable to select drug resistant mutants.

Antibiotic cross-resistance patterns of Md and Pz-resistant mutants

It may be noted from Table 2 that in *M. phlei* L1 the MIC of Md was 25 µg/ml, the first step mutant could be developed at 50 µg/ml of Md when the MIC of Md was found to be 100 µg/ml. From this the step 2 mutant of the same organism was developed whose MIC value of Md was 400 µg/ml. There was a gradual increase in the MIC values with respect to INH, Rf, Eb and Py while there was no change in MIC values with respect to Sm. A similar pattern was noted in *M. flavescens* 1541. However, in the Md- mutants of *M. avium* 724 and

M. gordonae 1324, MIC values decreased in case of Sm and Py respectively. *M. tuberculosis* H₃₇Rv 102 and Ra 16 being rather sensitive to test drugs, the levels of Md resistances in mutants of these strains were not so high and the changes in resistogramme pattern of mutants were not significant (Table 2). On the contrary, *M. tuberculosis* Bajaj 1, J15 and N23 being much less sensitive to the test agents, produced mutants at much higher levels of Md and simultaneously exhibited greater MICs with respect to all the antitubercular drugs except the strain N23 whose MIC value of Eb decreased in the mutants.

Table 2 Changing pattern of resistances of antimycobacterial drugs in methdilazine resistant mutants of *Mycobacterium* spp.

Mycobacteria	Types of cultures	MIC (µg/ml in LJM) of different agents for the wild type and mutant bacteria					
		INH	Rf	Eb	Py	Sm	Md
<i>M. phlei</i> L1	Wild Type	5	2	2	10	2	25
	Md mutant step 1 (50)	5	2	2	10	2	100
	Md mutant step 2 (200)	10	10	5	25	2	400
<i>M. flavescens</i> 1541	Wild Type	2	2	5	5	2	10
	Md mutant step 1 (25)	5	2	5	25	10	100
	Md mutant step 2(200)	5	2	10	25	25	500
<i>M. avium</i> 724	Wild Type	5	5	10	2	10	25
	Md mutant step 1 (50)	5	10	25	5	10	200
	Md mutant step 2(400)	5	10	25	5	5	100
<i>M. gordonae</i> 1324	Wild Type	2	2	2	5	2	10
	Md mutant step 1 (50)	2	2	2	2	2	200
	Md mutant step 2(400)	5	2	5	2	5	1000
<i>M. tuberculosis</i> Bajaj1	Wild Type	25	5	5	5	25	50
	Md mutant step 1 (100)	25	5	10	10	25	200
	Md mutant step 2(400)	50	5	10	25	25	500
<i>M. tuberculosis</i> J15	Wild Type	25	5	10	25	25	50
	Md mutant step 1 (200)	25	5	25	10	25	500
	Md mutant step 2(1000)	50	5	25	10	25	2000
<i>M. tuberculosis</i> N23	Wild Type	25	5	5	50	50	50
	Md mutant step 1 (200)	50	5	2	50	50	500
	Md mutant step 2(1000)	100	5	2	100	50	2000
<i>M. tuberculosis</i> H ₃₇ Rv102	Wild Type	2	2	5	5	2	10
	Md mutant step 1 (25)	2	2	10	5	5	100
	Md mutant step 2(200)	2	2	10	25	5	500
<i>M. tuberculosis</i> H ₃₇ Ra16	Wild Type	2	2	2	5	2	5
	Md mutant step 1 (25)	2	5	2	5	5	50
	Md mutant step 2(100)	5	5	2	2	5	200

*INH, isoniazid acid hydrazide; Rf, rifampicin; Eb, ethambutol; Py, pyrazinamide; Sm, streptomycin; Md, methdilazine

The step-wise mutants produced by mycobacteria against Pz showed nearly similar pattern of increase in resistances against the antitubercular drugs.

However, in case of *M. intracellulare* 1406 there was a loss in the MIC value of Eb (Table 3).

Table 3 Promethazine (Pz) resistant mutants of *Mycobacterium* spp. and their effects on change of resistant patterns with respect to anti-mycobacterial drugs

Mycobacteria	Types of cultures	MIC (µg/ml in LJM) of different agents with respect to wild type and mutant bacteria					
		INH	Rf	Eb	Py	Sm	Pz
<i>M. fortuitum</i> 1529	Wild Type	2	2	2	2	5	25
	Pz mutant step 1 (50)	5	2	2	5	5	100
	Pz mutant step 2 (200)	5	2	5	25	10	400
<i>M. scrofulaceum</i> 1323	Wild Type	2	1	2	2	2	10
	Pz mutant step 1 (25)	5	1	2	25	10	50
	Pz mutant step 2(100)	5	2	10	25	25	400
<i>M. marinum</i> 50	Wild Type	2	2	5	5	2	25
	Pz mutant step 1 (50)	5	5	25	5	5	100
	Pz mutant step 2(200)	5	10	25	5	5	400
<i>M. intracellulare</i> 1406	Pz mutant step 3(500)	10	25	50	10	5	1000
	Wild Type	5	5	5	5	2	25
	Pz mutant step 1 (50)	5	2	5	5	2	200
<i>M. tuberculosis</i> Bajaj1	Pz mutant step 2(400)	5	2	10	10	5	500
	Pz mutant step 3(1000)	25	2	50	25	10	2000
	Wild Type	25	5	5	5	25	50
<i>M. tuberculosis</i> J15	Pz mutant step 1 (100)	50	5	5	10	25	200
	Pz mutant step 2(400)	100	5	10	25	50	1000
	Wild Type	25	5	10	25	25	50
<i>M. tuberculosis</i> N23	Pz mutant step 1 (100)	25	10	25	10	50	200
	Pz mutant step 2(400)	25	10	50	10	50	1000
	Wild Type	25	5	5	50	50	50
<i>M. tuberculosis</i>	Pz mutant step 1 (100)	25	5	5	50	100	400
	Pz mutant step 2(500)	100	5	10	100	100	1000
	Wild Type	2	2	5	5	2	10

H ₃₇ Rv102	Pz mutant step 1 (25)	5	2	5	10	2	50
	Pz mutant step 2(100)	5	2	10	25	10	400
	Wild Type	2	2	2	5	2	5
<i>M.tuberculosis</i> H ₃₇ Ra16	Pz mutant step 1 (10)	2	2	2	5	2	25
	Pz mutant step 2(50)	10	5	5	5	5	100

*INH, isoniazid acid hydrazide; Rf, rifampicin; Eb, ethambutol; Py, pyrazinamide; Sm, streptomycin; Pz, promethazine

DICUSSION

Prevalence of cross-resistances between aminoglycosides in drug-resistant mutants of *M.tuberculosis* has been studied extensively. Resistance to kanamycin in viomycin-resistant strains and resistance to streptomycin in kanamycin-resistant strains were two to four times greater than the resistant levels of the parent strains of *M.tuberculosis* (Torii et al., 1959; Steenken et al., 1959). Tsukamura (1974) isolated two types of tuberactinomycin N resistant mutants of *M.tuberculosis*, the first one was resistant to low levels of tuberactinomycin N, viomycin and capreomycin, while the other was resistant at high levels to all these three antibiotics plus kanamycin and lividomycin. With the help of an intensive study Tsukamura and Mizuno in 1975 proved that aminoglycoside antibiotics could be classified into three major types: streptomycin resistance, combined viomycin-tuberactinomycin N- capreomycin resistance, and the third type included resistance to kanamycin, lividomycin and paramomycin. No cross-resistance between streptomycin and any other amionoglycoside antibiotic was observed. Although there is a large number of studies on clinical isolates of *M.tuberculosis* on mutations of genes and their relatedness of resistances to specific antibiotics (Taniguchi et al., 1996; Telenti et al., 1993; Ginsburg, 2005; Pitaksajjakul et al., 2005) evaluation of drug-resistance in experimentally produced mutants of *M.tuberculosis* has not been reported during past several years.

Imperiale et al (2014) studied cross-resistances to isoniazid, rifampicin and levofloxacin at a molecular level in clinical isolates of *M.tuberculosis*. With the help of microplate colorimetric method they determined MIC of isoniazid, ethionamide, rifampicin, rifabutin and moxifloxacin in the clinical isolates. Mutations conferring drug resistances were detected by GenoType MTBDR plus and DNA sequences. Isoniazid and ethionamide cross resistance was detected in 95.12 % of isoniazid resistant isolates harbouring a mutation in inhAP or inhA open reading frame, but rifabutin cross-resistance was observed in 90% of clinical isolates originally shown to be resistant to rifampicin. This study highlighted that the same mutation causing resistance to the first line antitubercular drugs can be responsible for resistance to their respective structural analogs. Such findings are expected to help clinicians to decide on the treatment regime.

In this study it has been observed that Md mutants of *M.phlei* L1 developed cross-resistance to INH, Rf, Eb and Py in stepwise manner but not to Sm; with respect to *M.flavescens* 1541 the Md mutants developed cross-resistances to INH, Eb, Py, Sm and not To Rf. Wild type clinical isolates *M.tuberculosis* Bajaj 1, J15 and N23 had much higher level of MIC of all the test drugs, except Rf. Surprisingly, step-up mutants of all these 3 strains failed to develop resistance to Rf as well. On the contrary, resistance level of Eb decreased in step-two mutants of *M.tuberculosis* N23. Similar decrease in MIC of Sm was noted in *M.avium* 724 (Table 2). The Pz-resistant step-three mutants of *M.marinum* 50 and *M.intracellulare* 1406 were resistant to Pz at very high levels and increase in MIC values of Eb in these mutants was also significantly high. The resistances of wild-type and mutant mycobacteria differed in most instances by sufficiently large margins (within the limits of confidence of the test system), and therefore appeared to be truly reflective of the actual resistance of such mycobacteria. It is unlikely that the low levels of resistances exhibited by some of the mutants were due to their reduced growth rate, incubation period was kept for sufficiently long period even for slow-growers and these resistances did not seem to depend on drug-modifying enzymes; these, therefore, should not affect their MIC determination. Indeed MICs of several test drugs were found to be elevated simultaneously. Thus these observations on cross-resistance seem to be more easily explainable on the basis of a non-specific reduction in cell membrane permeability of the various Md and Pz mutants in varying degrees and selectivity with respects to different test drugs. A literature survey on the MICs of different antibiotics shows that there had been a significant rise in the highest values that characterize drug resistant strains as well as the lowest values of MICs of drugs/antibiotics (characterizing sensitive strains) with respect to almost all groups of pathogenic bacteria during the last five decades since the beginning of antibiotic era (Garrod and O' Grady, 1971; Ray et al., 1980). Development of such resistances has been ascribed to "intrinsic resistance" which is an

evolutionary ancient phenotype and can be defined as resistance of any bacterial species to a particular drug/antibiotic that has not been acquired as a result of exposure to such agents (Fajardo et al., 2008). Intrinsic resistance is the result of reduced permeability of bacterial envelope and the activity of efflux pumps (Nikaido and Zgurskaya, 1999). This suggests that the main physiological role of the components of intrinsic resistance involves the prevention of toxic components by restricting the permeability of the cell or the active export of toxic compounds. However, intrinsic resistance of *M.tuberculosis* has been traditionally attributed to the unusual structure of its mycolic acid containing cell wall that contributes to the low permeability for antitubercular antibiotics and chemotherapeutics (Jarker and Nikaido, 1994). The role of efflux mechanisms has been recognized as an important factor in the natural resistances of mycobacteria against tetracyclines, aminoglycosides and fluoroquinolones (De Rossi et al., 2006). Even though mutations in several genes are evidently related to drug resistance in *M.tuberculosis* a large number of clinical isolates do not seem to present such classical mutations (Almeida Da Silva and Palomino, 2011). It is known that inadvertent and extensive use of antitubercular drugs in tuberculosis patients have continuously contributed to substantial increase in drug resistances in *M.tuberculosis* resulting in emergence of multi-drug resistant and extensively drug resistant strains.

In view of our data and other findings it may be stated that the overall elevation of MIC of antitubercular drugs could also be due to a prolonged and massive use of a vast number chemotherapeutics, many of which have undetected or unsuspected antimicrobial/antitubercular activities. A few among such drugs are several phenothiazines including Md and Pz (Molnar et al., 1977; Kristiansen and Vergemann, 1986; Ratnakar and Murthy, 1993; Chakrabarty et al., 1993; Dutta et al., 2009; Crowle et al., 1992; Amaral et al.,1996; van Ingen et al., 2009; Advani et al., 2012; Kristiansen et al., 2015). It may be plausible to presume that many or all of these drugs could have selected mutants resistant to themselves and non-specifically to other antitubercular drugs all at low levels, at the therapeutic dosages at which they are used, thus contributing towards a gradual rise of the baseline of MIC of antitubercular agents. The present study provides experimental evidences for one of such possibilities.

CONCLUSION

The accelerated speed with which tuberculosis has spread in all communities throughout the world and the higher frequency of infection by multidrug and extensively drug resistant *M. tuberculosis* have resulted in an alarming situation. In this study it was observed that many strains of *M.tuberculosis* could be inhibited by both the phenothiazines methdilazine and promethazine.Thus these findings open up a new arena of treatment for multidrug and extensively drug resistant mycobacteria. It may be pointed out here that a structurally similar phenothiazine, thioridazine, has been repeatedly proved to be a potent antitubercular drug. Both the two compounds methdilazine and promethazine are routinely used as antihistaminic drugs while thioridazine is an effective antipsychotic drug. It needs to be pointed out here that since both methdilazine and promethazine are given to patients as antihistaminics and not as neuroleptics development of track resistance is not possible on the basis of prescription. Since the structurally similar neuroleptic drug thioridazine has repeatedly shown to be active against *M.tuberculosis* all such phenothiazines may be grouped together to define the results as a " class mechanism". When the antihistaminic compounds methdilazine and promethazine were allowed to produce mutants resistant to either of them at higher levels, the organisms showed elevated levels of MIC of tested antitubercular drugs. Such a phenomenon may be attributed as intrinsic resistance, which is the result of reduced permeability of bacterial envelope alongwith action of efflux pumps,which, in turn, result in prevention of toxic components into the cell. Therefore, it may be plausible that prolonged and indiscriminate use of such phenothiazines having antitubercular action, often unknowingly, may have allowed development of mutants resistant to themselves and simultaneously cross-resistances to many routinely used antitubercular drugs.

REFERENCES

- Advani, M.J., Siddique, I., Sharma, P. & Reddy, H. (2012). Activity of trifluoperazine against replicating, Non-replicating and drug resistant *M. tuberculosis*. *PLoS ONE*, 7, 1-9. <http://dx.doi.org/10.1371/journal.pone.0044245>
- Almeida Da Silva, P. E. & Palomino, J. C. (2011). Molecular basis and mechanisms of drug resistance in *Mycobacterium tuberculosis*: classical and new drugs. *Journal of Antimicrobial Chemotherapy*, 66,1417–1430. <http://dx.doi.org/10.1093/jac/dkr173>
- Amaral, L., Kristiansen, J.E., Abebe, L.S. & Millett, W. (1996). Inhibition of the respiration of multi-drug resistant clinical isolates of *Mycobacterium tuberculosis* by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. *Journal of Antimicrobial Chemotherapy*, 38, 1049-1053. <http://dx.doi.org/10.1093/jac/38.6.1049>
- Barrow, G.I. & Feltham, R.K.A. (2003). In : Cowan and steel's manual for the identification of medical bacteria, third ed. Cambridge University Press, Cambridge
- Chakrabarty, A.N., Bhattacharya, C.P. & Dastidar, S.G. (1993). Antimycobacterial activity of methdilazine(Md), an antimicrobial phenothiazine. *Acta Pathologica Microbiologica et Immunologica Scandinavica*, 101, 449-454. <http://dx.doi.org/10.1111/j.1699-0463.1993.tb00133.x>
- Crowle, J.A., Douvas, G.S. & May, M.H. (1992). Chlorpromazine: A drug potentially useful for treating mycobacterial infections. *Chemotherapy*, 38, 410-419. <http://dx.doi.org/10.1159/000239036>
- Dastidar, S.G., Chaudhury, A., Annadurai, S., Roy, S., Mookerjee, M. & Chakrabarty, A.N. (1995). *In vitro* and *in vivo* antimicrobial action of fluphenazine. *Journal of Chemotherapy*, 7, 201-206. <http://dx.doi.org/10.1179/joc.1995.7.3.201>
- Dastidar, S.G., Debnath, S., Mazumdar, K., Ganguly, K. & Chakrabarty, A.N. (2004). Triflupromazine: a microbicide non-antibiotic compound. *Acta Microbiologica et Immunologica Hungary*, 51,75-83. <http://dx.doi.org/10.1556/amier.51.2004.1-2.5>
- Dastidar, S.G., Kristiansen, J.E., Molnar, J. & Amaral, L. (2013). Role of phenothiazines and structurally similar compounds of plant origin in the fight against infections by drug resistant bacteria. *Antibiotics*, 2, 58-71. <http://dx.doi.org/10.3390/antibiotics2010058>
- De Rossi, E., Ainso, J.A. & Riccardi, G. (2006). Role of mycobacterial efflux transporters in drug resistance : an unresolved question. *FEMS Microbiology Review*, 30, 36-52. <http://dx.doi.org/10.1111/j.1574-6976.2005.00002.x>
- Dutta, N.K., Mazumdar, K., Dasgupta, A. & Dastidar, S.G. (2009). Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against *Mycobacterium tuberculosis* in mice. *Journal of Medical Microbiology*, 58, 1667-1668. <http://dx.doi.org/10.1099/jmm.0.014027-0>
- Fajardo, A., Martinez-Martin, N., Mercadillo, M., Galtan-galan, J.C., Ghysels, B., Matthijs, S., Cornelis, P., Wehlmann, L., Tummler, B., Baquero, F. & Martinez, J.L. (2008). The neglected intrinsic resistome of bacterial pathogens. *PLoS ONE*, 3, e1619. <http://dx.doi.org/10.1371/journal.pone.0001619>
- Garrod, L.P. & O'Grady, F. (1971). *Antibiotics & Chemotherapy*. E. & S. Livingstone, Edinburgh & London.
- Ginsburg, A. (2005). Emergence of fluoroquinolone resistance in *Mycobacterium tuberculosis* during continuously dosed moxifloxacin monotherapy in a mouse model. *Antimicrobial Agents and Chemotherapy*, 49,3977–3979. <http://dx.doi.org/10.1128/aac.49.9.3977-3979.2005>
- Imperiale, B., Di Giulio, A.B., Cataldi, A.A. & Morcillo, N.S. (2014). Evaluation of *Mycobacterium tuberculosis* cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. *The Journal of Antibiotics*, 67,749–754. <http://dx.doi.org/10.1038/ja.2014.61>
- Jarker, V. & Nikaido, H. (1994). Mycobacterial cell wall structure and role in natural resistance to antibiotics. *FEMS Microbiology Letters*, 123, 11-18. <http://dx.doi.org/10.1111/j.1574-6968.1994.tb07194.x>
- Kamerbeek, J., Schouls, L., Kolk, A., van Agterveld, M., van Sooling, D., S. Kujiper, et al. (1997). Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *Journal of Clinical Microbiology*, 35, 907-914.
- Koseki, Y. & Okamoto, S. (1963). Studies on cross-resistance between capreomycin and certain other anti-mycobacterial agents. *Japanese Journal of Medicinal Science and Biology*, 16, 1-38. <http://dx.doi.org/10.7883/yoken1952.16.31>
- Kristiansen, J.E. (1979). Experiments to illustrate the effect of chlorpromazine on the permeability of bacterial cell wall. *Acta Pathologica Microbiologica et Immunologica Scandinavica*, 87, 317-319. <http://dx.doi.org/10.1111/j.1699-0463.1979.tb02445.x>
- Kristiansen, J.E. & Vergmann, B. (1986). The antibacterial effect of selected phenothiazines and thioxanthenes on slow growing mycobacteria. *Acta Pathologica Microbiologica et Immunologica Scandinavica*, 94, 393-398. <http://dx.doi.org/10.1111/j.1699-0463.1986.tb03073.x>
- Kristiansen, J.E., Dastidar, S.G., Palchoudhuri, S., Sinha Roy, D., Das, S., Hendricks, O. & Christensen, J.B. (2015). Phenothiazones as a solution for multidrug resistant tuberculosis: from the origin to present. *International Microbiology*, 18, 1-12
- Mazumdar, R., Ganguly, K., Dastidar, S.G. & Chakrabarty, A.N. (2001). Trifluoperazine: A broad-spectrum bactericide specially active on staphylococci and vibrios. *International Journal of Antimicrobial Agents*, 18, 403-406. [http://dx.doi.org/10.1016/s0924-8579\(01\)00324-7](http://dx.doi.org/10.1016/s0924-8579(01)00324-7)
- Maus, C.E., Plikaytis, B.B. & Shinnick, T.M. (2005). Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy*, 49, 3192–3197. <http://dx.doi.org/10.1128/aac.49.8.3192-3197.2005>
- Molnar, J., Beladi, I. & Foldes, I. (1977). Studies on anti-tuberculous action of some phenothiazine derivatives in vitro. *Zentralblatt für Bakteriologie (Orig A)*, 239, 521-526.
- Nikaido, H. & Zgurskaya, H.I. (1999). Antibiotic efflux mechanisms. *Current Opinion on Infectious Diseases*, 12,529-36. <http://dx.doi.org/10.1097/00001432-199912000-00001>
- Pitaksajakul, P., et al. (2005). Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant *Mycobacterium tuberculosis* from TB patients in Thailand, *Southeast Asian Journal of Tropical Medicine and Public Health*, 36, 228–237.
- Radhakrishnan, V., Ganguly, K., Ganguly, M., Dastidar, S.G. & Chakrabarty, A.N. (1999). Potentiality of tricyclic compound thioridazine as an effective antibacterial and antiplasmid agent. *Indian Journal of Experimental Biology*, 37, 671-675.
- Ratnakar, P. & Murthy, P.S. (1993). Trifluoperazine inhibits the incorporation of labelled precursors into lipids, proteins and DNA of *Mycobacterium tuberculosis* H37Rv. *FEMS Microbiology Letters*, 110, 291-294. [http://dx.doi.org/10.1016/0378-1097\(93\)90117-k](http://dx.doi.org/10.1016/0378-1097(93)90117-k)
- Ray, S., Dastidar, S.G. & Chakrabarty, A.N. (1980). Antibiotic cross-resistance patterns of ambodryl and promazine resistant mutants. *British Journal of Experimental Pathology*, 61,465.
- Steenken, W., Montalbino, V. & Thurston, R. (1959). The antituberculous activity of kanamycin *in vitro* and in the experimental animal (guinea pig). *American Review of Tuberculosis*, 79, 66-71. <http://dx.doi.org/10.1111/j.1749-6632.1958.tb54696.x>
- Suzuki, Y., Katsukawa, C., Tamaru, A., Abe, C., Makino, M., Mizuguchi, Y. & Taniguchi, H. (1998). Detection of kanamycin-resistant *Mycobacterium tuberculosis* by identifying mutations in the 16S rRNA gene. *Journal of Clinical Microbiology*, 36,1220–1225.
- Taniguchi, H., Aramaki, H., Nikaido, Y., Mizuguchi, Y., Nakamura, M., Koga, T. & Yoshida, S. (1996). Rifampicin resistance and mutation of the rpoB gene in *Mycobacterium tuberculosis*. *FEMS Microbiology Letters*, 144,103-108. <http://dx.doi.org/10.1111/j.1574-6968.1996.tb08515.x>
- Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M.J., Matter, L., Schopfer, K. & Bodmer, T. (1993). Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet*, 341,647-650. [http://dx.doi.org/10.1016/0140-6736\(93\)90417-f](http://dx.doi.org/10.1016/0140-6736(93)90417-f)
- Torii, F., Yamamoto, M., Hayashi, M., Noda, Y., & Tsukamura, M. (1959). Studies on the kanamycin resistance of *Mycobacterium tuberculosis*. II. Kanamycin-sensitivity of various drug-resistant strains. *Journal of Antibiotics*, 12, 103-104.
- Tsukamura, M. (1959). Further studies on the one-way cross-resistance in *Mycobacterium tuberculosis* with special reference to streptomycin resistance, kanamycin resistance, and viomycin resistance. *Japanese Journal of Genetics*, 34, 275-28. <http://dx.doi.org/10.1266/jjg.34.275>
- Tsukamura, M. (1969). Cross-resistance relationships between capreomycin, kanamycin and viomycin resistances in tubercle bacilli from patients. *American Review of Respiratory Diseases*, 99, 780-782.
- Tsukamura, M. (1974). Resistance pattern to tuberactinomycin-N and cross resistance relationships between tuberactinomycin-N, lividomycin, capreomycin, viomycin, kanamycin and streptomycin resistances of *Mycobacterium tuberculosis* (H₃₇ Rv). *Chemotherapy* (Tokyo), 22, 1115-1121.
- Tsukamura, M. & Mizuno, S. (1975). Cross-resistance relationships among the aminoglycoside antibiotics in *Mycobacterium tuberculosis*. *Journal of General Microbiology*, 88, 263-274. <http://dx.doi.org/10.1099/00221287-88-2-269>
- Van Ingen, J., van der Laan, T., Amaral, L., Dekhuijzen, R., Boeree, M.J. & van Sooling, D. (2009). *In vitro* activity of thioridazine against mycobacteria. *International Journal of Antimicrobial Agents*, 34,190-191. <http://dx.doi.org/10.1016/j.ijantimicag.2009.02.015>
- World Health Organization (2013) Global Tuberculosis Report. WHO, Geneva, Switzerland.